Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Palliative thoracic radiotherapy versus docetaxel maintenance after first-line gemcitabine plus platinum in advanced central squamous lung cancer
ChiCTR-IPR-15006594Phase 2Not yet recruiting
- Sponsor
- Shanghai Pulmonary Hospital
- Start
- Jul 2015
- Modality
- Classical Binding Small Molecules → Small Molecules, Covalent Small Molecules → Small Molecules, Nucleic Acid-Directed Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised, open-label trial of docetaxel in Pulmonary squamous cell carcinoma (2 arms), sponsored by Shanghai Pulmonary Hospital. Primary endpoint: Overall survival. Planned start Jul 2015; status: not yet recruiting.
02
Drugs
docetaxel
03
Conditions
Pulmonary squamous cell carcinoma
Beyond the preview
Go deeper on ChiCTR-IPR-15006594.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR-IPR-15006594.